Prostate Cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Initial puncture pathology or postoperative pathology confirms GS 9-10 points. 2.Patients with radiological confirmation of distant metastases. 3.Treatment regimen: all-site radiotherapy + standard systemic therapy (ADT + novel hormonal therapy ± chemotherapy). The radiotherapy protocol includes: all-site radiotherapy targeting all metastatic lesions or all residual active disease following systemic therapy. 4.Expected survival exceeding 12 months. 5.Age >= 18 years. 6.KPS>=80 points. 7.White blood cell count >= 3.5 × 10^9/L, neutrophil count >= 1.5 × 10^9/L, platelet count >= 100.0 × 10^9/L, haemoglobin >= 90 g/L. 8.Informed consent of the subject.
Exclusion criteria
Exclusion criteria: 1.Previous history of malignant tumors (except for tumors that have been cured for more than 5 years). 2.Previous abdominal radiotherapy. 3.Weight loss exceeding 10% within the past six months. 4.Individuals with pre-existing or concomitant bleeding disorders. 5.Active infection. 6.Clinically evident cardiac disease (e.g., drug-resistant hypertension, unstable angina pectoris, congestive heart failure at New York Heart Association [NYHA] class >= II, unstable symptomatic arrhythmia, or peripheral vascular disease at >= NYHA class II). 7.Individuals are unable to provide informed consent due to psychological, familial, or social factors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Castration-Resistant Prostate Cancer-Free Survival;Progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival;PSA progression-free survival;Prostate Cancer-Specific Survival; | — |
Countries
China
Contacts
Peking University First Hospital